Stabvida

STAB VIDA is a biotech SME with a dedicated line of products and services for genetics, genomics and immunology.

Recently, we have developed an IVD for Lyme Disease (LD) to allow a faster and more accurate diagnostic of the disease in clinical laboratories.

Now we wish to bring this knowledge directly to clinics and hospitals with a Point-of-Care platform that allows a sample-to-clinical report in 15 minutes.

LD is the most common tick-borne infection in Europe and North America. Current diagnostic tests lack the sensitivity and efficiency to detect both early stage and chronical stages of LD.

STAB VIDA is looking for an investment of ~3M Euros to take our innovative PoC-IVD prototype to the market and revolutionize the LD market.